15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 23 firms covering AbbVie Inc, 20 rate it Buy or better, 3 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets are tightly clustered, $247.00 to $303.00, so the covering firms are broadly aligned. The average target of $279.00 sits 12% above the current $248.70. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 15 to 20 over recent months. On the fundamentals, the Street sees revenue growth near 10% this year and 8% next, consensus EPS building from about $3.87 next quarter toward $16.28 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS23 ratings
Strong Buy
Strong Buy00%
Buy2087%
Hold313%
Sell00%
Strong Sell00%
Based on 23 analysts giving stock ratings to AbbVie Inc.
As of Sep, 20 of 23 firms rate ABBV a Buy (3 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
ABBV EPS & revenue forecast
EPS · NEXT QUARTER
$3.87
Range $3.76 – $3.98 · 17 analysts · +43% YoY
Next period, 17 analysts expect AbbVie Inc to earn $3.87 a share (range $3.76 – $3.98), versus $2.71 a year earlier. Full-year consensus is $14.01, growing to $16.28 the year after.
REVENUE · NEXT QUARTER
$18.3B
Range $18.1B – $18.5B · 17 analysts · +10% YoY
Revenue is expected to reach $18.3B (range $18.1B – $18.5B), +10.0% year-over-year. Full-year consensus is $67.6B, rising to $73.5B next year.
Top analysts covering AbbVie Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ABBV.
#1
David Amsellem
Piper Sandler · Rank #107
Buy
$303.00+21.8% to target
Overall win rate
50%
+ Follow
#2
Jason Gerberry
B of A Securities · Rank #125
Buy
$276.00+11.0% to target
Overall win rate
46%
+ Follow
#3
GN
Gary Nachman
Canaccord Genuity
Buy
$290.00+16.6% to target
Coverage
—
+ Follow
#4
Vamil Divan
Guggenheim
Buy
$288.00+15.8% to target
Coverage
—
+ Follow
#5
Carter Gould
Cantor Fitzgerald
Buy
$285.00+14.6% to target
Coverage
—
+ Follow
ABBV stock forecast FAQ
What is ABBV's average 12-month price target?+
The 18 analysts with a live target average $279.00 for AbbVie Inc over the next 12 months, ranging from a $303.00 high to a $247.00 low.
Is ABBV stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 23 analyst ratings, 20 are Buy or Strong Buy, 3 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for ABBV?+
The Street-high target is $303.00 (Piper Sandler), and the Street-low is $247.00 (BNP Paribas). The average of all 18 active targets is $279.00.
How many Wall Street analysts cover ABBV?+
23 analysts have an active rating on AbbVie Inc, and 18 firms carry a live 12-month price target.
Who is the most accurate analyst covering ABBV?+
Among analysts who currently cover ABBV, David Amsellem of Piper Sandler has the strongest overall Quantellect track record (Rank #107). Their current call is Buy with a $303.00 target.
What is AbbVie Inc's projected EPS for next quarter?+
The consensus estimate is $3.87 per share (range $3.76 – $3.98) across 17 analysts. Full-year EPS is projected at $14.01, rising to $16.28 the following year.
How much revenue is AbbVie Inc expected to report next quarter?+
Consensus revenue is $18.3B (range $18.1B – $18.5B). Full-year revenue is projected at $67.6B, growing to $73.5B next year.
Have analysts been upgrading or downgrading ABBV lately?+
As of Sep, 20 of 23 firms rate ABBV a Buy (3 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ABBV calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
